Hackensack Meridian Health Convalescent Plasma Work for COVID-19 Treatments Enters Next Phase of Study

The new Phase 2 study is for infusing this potentially valuable serum into patients with early-stage COVID-19 infection who have at least one major risk factor for serious disease, in an outpatient setting. The goal is to treat the patients in the first 96 hours – with the aim to prevent hospitalization entirely.

Q&A with Clinical Trial Investigator at UC San Diego Health on How a Century-old Treatment May Prevent COVID-19 in Persons After Exposure

Most media and public attention during the pandemic has focused upon efforts to develop an effective vaccine to prevent COVID-19, which is caused by the novel coronavirus SARS-CoV-2. Some attention has been paid to investigational therapeutics for treating infected patients,…

60-day follow-up of 300+ COVID-19 patients demonstrates convalescent plasma therapy is safe and effective

A follow-up Houston Methodist study of 351 COVID-19 patients treated with convalescent plasma therapy concludes those patients receiving convalescent plasma with a very high antibody content – or high titer – within 72 hours of hospitalization were significantly more likely to survive SARS-CoV-2 coronavirus infection. The results confirm and extend scientific evidence from an earlier interim study and show transfusion of high-titer convalescent plasma has maximum beneficial effect if given within 44 hours of hospitalization.

Study takes us a step closer to a universal antibody test for COVID-19

A study released by Houston Methodist Sept. 10 in the Journal of Clinical Investigation takes researchers closer to developing a uniform, universal COVID-19 antibody test. The multicenter collaboration tested alternative ways to measure COVID-19 antibody levels that’s faster, easier and can inexpensively be used on a larger scale to accurately identify potential donors for plasma therapy with the best chance of helping patients infected with SARS-CoV-2.

Team is first in Texas to join NIH study investigating efficacy of convalescent plasma for COVID-19

Using a multimillion-dollar grant from the NIH, physician-scientists at The University of Texas Health Science Center at Houston (UTHealth) will investigate whether convalescent plasma infusions can prevent the progression of COVID-19 in one of the first randomized clinical trials in the country.

Baylor Scott & White Research Institute Expands Efforts in the Fight Against COVID-19

As the global response to the SARS-COV-2 virus that causes COVID-19 approaches 200 days, Baylor Scott & White Research Institute, the research and development arm of Baylor Scott & White Health, is accelerating its pace of bringing clinical trials online.

Baylor Scott & White Research Institute continues to mobilize staff and resources, including components needed to integrate critical patient-safety measures at every participating site within the Baylor Scott & White system for industry sponsored drug trials, investigator-initiated drug trials and research studies, and observational and data studies designed to help increase knowledge around case trends, viral epidemiology, and care best practices.

Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense Funding

Mount Sinai and Emergent to conduct clinical trials to evaluate COVID-HIG for post-exposure prophylaxis of COVID-19 in front-line health care workers and to support a potential Expanded Access Program for military personnel with funding from the U.S. Department of Defense
– ImmunoTek to extend operating license and provide training to Mount Sinai to establish onsite plasma collection to support production of COVID-HIG

Jersey Shore University Medical Center Treating COVID-19 Patients with Convalescent Plasma

As a leading New Jersey academic medical center and member of Hackensack Meridian Health, Jersey Shore University Medical Center is able to provide its patients access to existing clinical trials and the latest medical techniques in a variety of specialties. Currently, the medical center is recruiting individuals who have been clinically diagnosed with COVID-19 or have laboratory test results showing they have COVID-19 antibodies to donate their blood and potentially assist patients in their recovery from the virus.

Convalescent Plasma Is A Potentially Effective Treatment Option for Patients Hospitalized With COVID 19, According to Early Data

Patients hospitalized with COVID-19 who received convalescent plasma demonstrated improved survival and were more likely than matched control patients to remain the same or have improvements in their supplemental oxygen requirements, according to a study conducted by researchers at the Icahn School of Medicine at Mount Sinai and published today on pre-print server medRxiv.

Study finds COVID plasma therapy safe, with 76% patients improving

The first convalescent plasma transfusion trial results from Houston Methodist have been released. Of the 25 patients in the study, 19 have improved and 11 have been discharged. With no adverse side effects caused by the therapy, the study concluded that convalescent plasma is a safe treatment option for patients with severe COVID-19. This is the largest cohort assessed for outcomes related to convalescent plasma therapy for COVID-19.

Research and innovation as an essential function amid the COVID-19 pandemic

Necessity being the mother of invention, Houston Methodist clinicians, researchers and staff have collaborated on a number of clinical device and research innovations in response to COVID-19. Houston Methodist Academic Institute leadership has continually emphasized translational research in new technologies.